O.N. Diagnostics
Private Company
Funding information not available
Overview
O.N. Diagnostics is a pioneer and leader in Biomechanical Computed Tomography (BCT), a novel diagnostic paradigm for osteoporosis and fracture risk assessment. Founded in 2005, the company has developed and commercialized VirtuOst, the first-ever FDA-cleared BCT software, which extracts comprehensive bone quality data from existing patient CT scans without requiring additional radiation or special protocols. The company operates a dual business model, offering its VirtuOst analysis as a clinical diagnostic service while also providing extensive contract research services to academic, government, and industry partners, leveraging its technology to support regulatory submissions and product development.
Technology Platform
Biomechanical Computed Tomography (BCT) / Finite Element Analysis (FEA) software that performs virtual stress tests on bone using standard CT scans to measure bone strength and fracture risk.
Opportunities
Risk Factors
Competitive Landscape
O.N. Diagnostics competes with traditional DXA scan providers but offers a superior, strength-based assessment. It is a first-mover in FDA-cleared Biomechanical CT analysis, though other companies and academic institutions are developing advanced CT-based bone analysis techniques. Its unique regulatory precedent in device approval creates a significant competitive moat in the research services segment.